Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : This year symbols : ALNY save search
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -1.17%
H: 1.01%
C: 0.11%
first conference financial results
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Published: 2024-03-20 (Crawled : 13:00) - biospace.com/
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.11%
H: 0.43%
C: -0.01%
cardiology results study
Rapport Therapeutics Appoints Pioneering Industry Leader John Maraganore to Board of Directors
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.33%
H: 1.88%
C: 0.84%
therapeutics
Zenas BioPharma Appoints Patricia Allen to its Board of Directors
Published: 2024-03-06 (Crawled : 16:00) - biospace.com/
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.31%
H: 0.06%
C: -0.33%
biopharma
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
positive blood care topline results study
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
Published: 2024-03-05 (Crawled : 15:30) - biospace.com/
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -0.09%
H: 2.06%
C: -2.68%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
hepatitis trial
Alnylam to Webcast Presentations at Upcoming March Investor Conferences - February 27, 2024
Published: 2024-02-27 (Crawled : 14:00) - biospace.com/
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.84%
H: 0.82%
C: -0.63%
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-22 (Crawled : 00:00) - biospace.com/
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.87%
H: 2.89%
C: 2.14%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -0.69%
H: 2.99%
C: 2.59%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.17%
H: 6.18%
C: 5.4%
year update financial results
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
Published: 2024-02-15 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -8.62%
H: 2.18%
C: -1.71%
year pharmaceuticals financial results
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.32%
H: 0.11%
C: -1.55%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -2.63%
H: 0.98%
C: -1.75%
liver disease therapeutics market
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
TSVT | $4.52 -2.59% -2.65% 610K
|
|
| O: -1.16%
H: 9.94%
C: 2.34%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 1.4%
H: 0.28%
C: -2.68%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -1.23%
H: 1.0%
C: 0.17%
year financial results
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-01-29 (Crawled : 14:30) - biospace.com/
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.27%
H: 1.32%
C: 1.02%
conference year financial results
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Published: 2024-01-22 (Crawled : 22:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
MDGL | $212.33 -4.47% -4.68% 620K
|
Health Technology
|
| O: 1.29%
H: 0.35%
C: -3.04%
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: -0.48%
H: 7.69%
C: 1.44%
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: -0.8%
H: 6.02%
C: 0.6%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.46%
H: 3.04%
C: 2.67%
ETNB | $9.08 2.25% 2.2% 1M
|
Health Technology
|
| O: 1.19%
H: 0.63%
C: -0.72%
liver disease companies key growth market
Opinion: Brain Health Matters; We Must Not Lose Momentum
Published: 2024-01-08 (Crawled : 07:00) - biospace.com/
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.05%
H: 4.12%
C: 3.98%
health momentum
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 13:30) - biospace.com/
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.8%
H: 3.23%
C: 2.66%
conference presentation
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.